The SEC says a former executive at Medivation bought stock in another cancer drug development company days before his company announced a $14 billion deal with Pfizer.Alleged ‘shadow trading’ leads SEC to charge Bay Area biotech exec five years later
The SEC says a former executive at Medivation bought stock in another cancer drug development company days before his company announced a $14 billion deal with Pfizer.
